Open-label Study of Dupilumab in Patients With Atopic Dermatitis
An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
Sponsor: Regeneron Pharmaceuticals
A PHASE3 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 13 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Nov 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Mar 2019 — Jul 2019 [monthly]
Unknown Status PHASE3
Status: Enrolling By Invitation → Unknown Status
-
Jun 2018 — Mar 2019 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Ajax, Canada , Albuquerque, United States , Alpharetta, United States , Amagasaki, Japan , Amsterdam, Netherlands , Ancona, Italy , Anniston, United States , Arlington, United States , Atlanta, United States and 308 more locations